Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Hughes

Showing results (71-80 of 97) with videos related to

Pageof 10
Sort By:
Emerging Infectious Diseases|August 1, 2017
Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant TuberculosisJay Achar, Cathy Hewison, Ana P Cavalheiro, et al.
Frontiers in Drug Delivery|August 21, 2025
Characterization of large volume subcutaneous injections using computed tomography imaging and simultaneous pressure measurementsMona Purcell, Sahab Babaee, Michael Galluppi, et al.
The Lancet. Infectious Diseases|February 18, 2018
Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort studyGabriella Ferlazzo, Erika Mohr, Chinmay Laxmeshwar, et al.
The European Respiratory Journal|May 31, 2020
Responding to SARS-CoV-2 in South Africa: what can we learn from drug-resistant tuberculosis?Norbert Ndjeka, Francesca Conradie, Graeme Meintjes, et al.
The European Respiratory Journal|July 25, 2020
Correspondence regarding "Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa"Erika Mohr-Holland, Anja Reuter, Jennifer Hughes, et al.
Plos One|November 12, 2015
Time to ART Initiation among Patients Treated for Rifampicin-Resistant Tuberculosis in Khayelitsha, South Africa: Impact on Mortality and Treatment SuccessJohnny Flippie Daniels, Mohammed Khogali, Erika Mohr, et al.
Bulletin of the World Health Organization|January 7, 2014
Principles for designing future regimens for multidrug-resistant tuberculosisGrania Brigden, Bern-Thomas Nyang'wa, Philipp du Cros, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|December 1, 2006
Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS)Betsy Kennard, Susan Silva, Benedetto Vitiello, et al.
The Lancet. Infectious Diseases|May 5, 2022
Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort studyNorbert Ndjeka, Jonathon R Campbell, Graeme Meintjes, et al.
Biology of Reproduction|January 26, 2008
Gamendazole, an orally active indazole carboxylic acid male contraceptive agent, targets HSP90AB1 (HSP90BETA) and EEF1A1 (eEF1A), and stimulates Il1a transcription in rat Sertoli cellsJoseph S Tash, Ramappa Chakrasali, Sudhakar R Jakkaraj, et al.
Pageof 10

Showing results (71-80 of 97) with videos related to

Sort By:
Pageof 10
Emerging Infectious Diseases|August 1, 2017
Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant TuberculosisJay Achar, Cathy Hewison, Ana P Cavalheiro, et al.
Frontiers in Drug Delivery|August 21, 2025
Characterization of large volume subcutaneous injections using computed tomography imaging and simultaneous pressure measurementsMona Purcell, Sahab Babaee, Michael Galluppi, et al.
The Lancet. Infectious Diseases|February 18, 2018
Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort studyGabriella Ferlazzo, Erika Mohr, Chinmay Laxmeshwar, et al.
The European Respiratory Journal|May 31, 2020
Responding to SARS-CoV-2 in South Africa: what can we learn from drug-resistant tuberculosis?Norbert Ndjeka, Francesca Conradie, Graeme Meintjes, et al.
The European Respiratory Journal|July 25, 2020
Correspondence regarding "Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa"Erika Mohr-Holland, Anja Reuter, Jennifer Hughes, et al.
Plos One|November 12, 2015
Time to ART Initiation among Patients Treated for Rifampicin-Resistant Tuberculosis in Khayelitsha, South Africa: Impact on Mortality and Treatment SuccessJohnny Flippie Daniels, Mohammed Khogali, Erika Mohr, et al.
Bulletin of the World Health Organization|January 7, 2014
Principles for designing future regimens for multidrug-resistant tuberculosisGrania Brigden, Bern-Thomas Nyang'wa, Philipp du Cros, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|December 1, 2006
Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS)Betsy Kennard, Susan Silva, Benedetto Vitiello, et al.
The Lancet. Infectious Diseases|May 5, 2022
Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort studyNorbert Ndjeka, Jonathon R Campbell, Graeme Meintjes, et al.
Biology of Reproduction|January 26, 2008
Gamendazole, an orally active indazole carboxylic acid male contraceptive agent, targets HSP90AB1 (HSP90BETA) and EEF1A1 (eEF1A), and stimulates Il1a transcription in rat Sertoli cellsJoseph S Tash, Ramappa Chakrasali, Sudhakar R Jakkaraj, et al.
Pageof 10